Drug intelligence / Profile preview

SCTV02

Development stage: Phase 2
Lead developer: Sinocelltech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SCTV02 is a recombinant protein vaccine developed for the prevention of diseases caused by respiratory syncytial virus (RSV) infection. RSV is a major cause of lower respiratory tract infections such as bronchiolitis and pneumonia in infants, and upper respiratory tract infections in older children and adults. SCTV02 is being evaluated in clinical trials for its safety, tolerability, and immunogenicity in healthy adults. The vaccine is being developed by Sinocelltech Group and has received approval to begin Phase 1/2 clinical trials in China[1][2][3].

Beyond the preview

Go deeper on SCTV02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCTV02.

Explore the full profile